Regorafenib Catalog No.:M10913-10 Smiles: CN(C)C1C=CC(=CC=1)C(C1=CC(=CC=C1Cl)[N+]([O-])=O)C1C=CC(=CC=1)N(C)C

Smiles: CN(C)C1C=CC(=CC=1)C(C1=CC(=CC=C1Cl)[N+]([O-])=O)C1C=CC(=CC=1)N(C)C

and chimeric mouse studies

despite the lack of progress in achieving markedly higher solubility

The oxocarbazate caused a time-dependent 17-fold drop in IC50 from 6

AZM475271 suppresses tumor growth and metastasis in vitro and in vivo potentially by anti-angiogenic mechanisms

Regorafenib Catalog No.:M10913-10 Smiles: CN(C)C1C=CC(=CC=1)C(C1=CC(=CC=C1Cl)[N+]([O-])=O)C1C=CC(=CC=1)N(C)CRegorafenib, also known as BAY 73 4506 ; is a n orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic